Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.63 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.63 |
| ▸ | CTSD | P07339 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.45 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10122269 | 1.00 | HTR3A (0.63) | HTR3AHTR4CTSDKMT2AMEN1 | |
| SCHEMBL9532735 | 0.89 | SLC6A2 (0.54) | HTR3AHTR4KMT2AMEN1RAB9A | |
| SCHEMBL9790164 | 0.89 | SLC6A2 (0.54) | HTR3AHTR4KMT2AMEN1RAB9A | |
| SCHEMBL9790170 | 0.89 | SLC6A2 (0.54) | HTR3AHTR4KMT2AMEN1RAB9A | |
| SCHEMBL7300279 | 0.86 | MEN1 (0.51) | HTR3AHTR4CTSDKMT2AMEN1 | |
| SCHEMBL9721683 | 0.82 | HTR3A (0.53) | HTR3AHTR4 | |
| SCHEMBL9721577 | 0.82 | HTR3A (0.53) | HTR3AHTR4 | |
| SCHEMBL7293769 | 0.82 | HTR3A (0.53) | HTR3AHTR4 | |
| SCHEMBL9721673 | 0.82 | HTR3A (0.53) | HTR3AHTR4 | |
| SCHEMBL9721569 | 0.82 | HTR3A (0.53) | HTR3AHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114880-B2 | Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid MTP inhibiting compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-20090325980-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325980-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | PNLIP, APOB, LIPC | HTR3A 3654/4885HTR4 3253/4885CTSD 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.